A new study has found that use of the Boston Scientific (NYSE:BSX) Watchman left atrial appendage closure (LAAC) device to treat atrial fibrillation costs less than existing and novel anticoagulant drugs over five years.
The retrospective study pooled data from the randomized trials of the Marlborough, Mass.-based company’s Watchman device. The PROTECT AF study measured Watchman’s effectiveness in preventing embolism, while the PREVAIL trial compared its use to long-term treatment with the anticoagulant drug warfarin.
